DSB 2455
Alternative Names: DSB-2455Latest Information Update: 26 Jul 2024
At a glance
- Originator Duke Street Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Jun 2024 Duke Street Bio plans a phase I trial for Solid tumours (Monotherapy, Combination-therapy, Late-stage disease, Second-line therapy or grater, Metastatic disease) (PO), in September 2024 (NCT06458712)
- 01 Dec 2023 Preclinical trials in Solid tumours in United Kingdom (PO), prior to December 2023
- 01 Dec 2023 Pharmacokinetics and pharmacodynamics data from preclinical trial in Solid tumours released by Duke Street Bio